3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
113
Colonic Neoplasms
30
Neoplasm Metastasis
28
Rectal Neoplasms
27
Neoplasms
27
Carcinoma, Non-Small-Cell Lung
14
Esophageal Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
9
Pancreatic Neoplasms
9
Head and Neck Neoplasms
9
Lung Neoplasms
8
Cholangiocarcinoma
7
Carcinoma, Squamous Cell
6
Breast Neoplasms
6
Colorectal Cancer Metastatic
5
Carcinoma
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Inflammatory Breast Neoplasms
3
Gastrointestinal Neoplasms
3
Adenocarcinoma Of Esophagus
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Kidney Neoplasms
2
Glioma
2
Fallopian Tube Neoplasms
2
Interventions
trifluridine tipiracil drug combination
1
Trastuzumab
1
Panitumumab
1
Oxaliplatin
1
Nivolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Dihydropyrimidine Dehydrogenase Deficiency
×
Panitumumab
×
Clear all
NCT06245356
2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2
Recruiting
73 enrolled